Skip to main content
Equibles
APRE logo

APRE · Aprea Therapeutics, Inc.

Track APRE — free

Use APRE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research APRE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.52 -0.01 (-1.86%)
Rebalance outlook locked
Market Cap
$6.56M
Shares
12.59M
Volume · Oct 20 317.81K Avg daily vol (3M) 283.32K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.53 Open$0.60 Day$0.53–0.61 52W close$0.53–1.65 Avg vol 30d224K Short int509K · 4.0% float · 2.5d Short vol44% Last earningsMay 16, 2022 DataJan 2020–Oct 2026 Filing10-Q · Aug 12

Up next

Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$12.31M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$41.23M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+779.2%
Year over year · more shares
Price change (1Y)
-66.1%
Trailing year
Short interest
4.0%
Latest settlement · 2.5 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −31%
below
Price vs 50-day avg −26%
below
RSI (14) 32
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −28%
trailing
6-month return −36%
trailing
YTD return −38%
this year
Relative strength −44%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
1 of 27 funds reported for Sep 30 · net +40 sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.04% of float · ▼ -11.4% MoM · 2.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
27 holders — mid 3-yr range
Squeeze score 51
elevated · 0–100
Fundamentals
Fair
EPS growth +18%
Y/Y
Free cash flow $-12.9M
Quant / Vol
risk profile
Very High
Volatility 95%
annualized · 1-yr
Max drawdown −68%
past year
ATR 11.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−31% Bearish
Price vs 50-day avg
−26% Bearish
RSI (14)
32 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
1 of 27 funds reported for Sep 30 · net +40 sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.04% of float · ▼ -11.4% MoM · 2.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
27 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $2
vs 200-day avg -31% vs 50-day avg -26%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
APRE
Aprea Therapeutics, Inc.
this stock
$6.56M -37.6% — — 4.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +10.7% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +669.4% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +1.3% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $64.50B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
28
% held
18.8%
Reported
1 of 27
Top holder
AIGH Capital Management L…
Held Float
View
Held by Funds
Fund positions
8
View
Short & Settlement
Short Interest Falling
Shares short
508.8K
Days to cover
2.5d
Change
-65.8K sh
View
Short Volume
Short vol %
44%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
4.3K
Value
$3.3K
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
57.8%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-12.6M
EPS diluted
$-1.93
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 28, 2026
This year
16
View
Exempt Offerings
Offering
$5.8M
Filed
Dec 29, 2025
View
Earnings & Events
Webcasts
Last webcast
May 16, 2022
View

Performance

5D 20D 120D MTD YTD
APRE -10.3% -27.8% -36.4% -29.0% -37.6%
SPY -1.5% -0.9% +7.7% +0.5% +12.4%
vs SPY -8.8% -26.9% -44.1% -29.5% -50.0%
Key facts CIK 1781983 CUSIP 03836J201 13F (30d) 1 filings 1 filers Visit website Investor relations